Loading
A phase 2 trial of Zanubrutinib in chronic lymphocytic leukaemia, run by Curis, Inc., now recruiting.
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies is a phase 2 interventional study registered as NCT07271667 by Curis, Inc., with 108 participants planned, started 2026-04-23 and due to reach its primary completion in 2027-11. Interventions recorded: Emavusertib and Zanubrutinib.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Emavusertib, Curis and the tag pipeline.
Shares Zanubrutinib, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Zanubrutinib, Chronic lymphocytic leukaemia and the tag pipeline.
Shares Zanubrutinib and the tag pipeline.
Shares Zanubrutinib and the tag pipeline.
Shares Zanubrutinib and the tag pipeline.
Shares Zanubrutinib and the tag pipeline.
Shares Chronic lymphocytic leukaemia and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/